Advertisement

Topics

FDA Approves Merck’s Prevymis for Prevention of Cytomegalovirus Infection in HSCT Patients

10:26 EST 9 Nov 2017 | Speciality Pharma Journal

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS™ (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult …

Original Article: FDA Approves Merck’s Prevymis for Prevention of Cytomegalovirus Infection in HSCT Patients

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Merck’s Prevymis for Prevention of Cytomegalovirus Infection in HSCT Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...